Small molecule · Agonist of angiotensin II type 2 receptor (AGTR2) · developed by Vicore Pharma
C106 is a selective nonpeptide agonist of the angiotensin II type 2 receptor (AT2R). It is being studied in idiopathic pulmonary fibrosis and pulmonary hypertension.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05427253 | Phase 1 | Safety Issues | Completed | VCRE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Idiopathic Pulmonary FibrosisPulmonary HypertensionSafety IssuesTolerance
Updated Nov 1, 2026. Something wrong or missing? Report it on the VCRE page.
See VCRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VCRE catalysts and pipeline →